CEBPA and leukemia: Considering that rapamycin regulates AML through a variety of pathways, such as inhibiting AML cell viability via circ_0094100/miR-217/ATP1B1 axis50 or enhancing the anti-leukaemia effect as a specific inhibitor of mTOR51, we overexpressed C/EBPα-p30 in THP-1 cells treated with PMA and rapamycin.